12:00 AM
 | 
Jan 19, 2009
 |  BC Week In Review  |  Company News  |  Deals

Xenome, AstraZeneca deal

AstraZeneca's MedImmune Inc. subsidiary will screen Xenome's bioactive peptide library to discover drug candidates against two undisclosed pain targets. MedImmune has...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >